Company Overview
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -18.13% |
| 6 Months: | -12.08% |
| 3 Months: | +3.15% |
| 1 Month: | -7.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 55.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MAIA MAIA Biotechnology, Inc. PHARMA | 1.31 | -2.08 | $79.69M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -2.23M | -3.44M | -3.44M | -5.10M | -4.18M | -4.66M | -4.96M | -3.95M | -3.82M | -4.19M | -5.43M | -5.17M | -9.36M | -6.95M | -8.32M |
| Net Income | -3.43M | - | - | -3.31M | - | - | - | - | -8.07M | -8.88M | -2.74M | -4.52M | -5.35M | -8.90M | -6.37M | -7.94M |
| Diluted EPS | -0.78 | -1.02 | -0.50 | -0.40 | -0.48 | -0.38 | -0.35 | -0.36 | -0.46 | -0.40 | -0.11 | -0.16 | -0.18 | -0.27 | -0.14 | -0.13 |
| R&D Expense | 643.99K | 1.08M | 2.08M | 2.12M | 2.34M | 2.20M | 2.60M | 2.60M | 2.32M | 2.05M | 2.67M | 3.20M | - | - | 43.65K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | - |
| Operating Income | -7.79M | -16.18M | -20.18M | -16.96M | -24.27M |
| Net Income | -12.50M | -16.22M | -19.77M | -23.25M | -22.40M |
| Diluted EPS | -2.37 | -1.75 | -1.49 | -1.05 | -0.70 |
| R&D Expense | 3.50M | 8.93M | 11.11M | 10.01M | 453.75K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 11.33M | 12.02M | 7.57M | 10.16M | 9.70M |
| Total Equity | -1.62M | 9.18M | 8.51M | 477.51K | 3.63M | 2.38M |
| Cash & Equivalents | - | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | - | 2.15M | 3.51M | 7.09M | 6.52M | 7.33M |
| Current Liabilities | - | 2.15M | 3.27M | 4.94M | 3.83M | 5.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -4.12M | -12.10M | -13.07M | -15.70M | -18.84M |
| Financing Cash Flow | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | -136.2% | -190.6% | -4,140.8% | -639.8% | -942.7% |
| ROCE % | -84.8% | -184.8% | -767.5% | -268.1% | -627.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Solas Capital Management, LLC | 4.98% | 3.03M | $3.97M |
| 2 | Alyeska Investment Group, L.p. | 4.11% | 2.50M | $3.27M |
| 3 | Vanguard Capital Management LLC | 3.97% | 2.41M | $3.16M |
| 4 | 683 Capital Management LLC | 1.75% | 1.07M | $1.40M |
| 5 | Centric Wealth Management | 1.31% | 796.72K | $1.04M |
| 6 | Cable Car Capital, LP | 0.85% | 514.58K | $674.10K |
| 7 | Geode Capital Management, LLC | 0.83% | 504.38K | $660.74K |
| 8 | Bleichroeder LP | 0.82% | 500.00K | $655.00K |
| 9 | Renaissance Technologies, LLC | 0.68% | 415.70K | $544.57K |
| 10 | Blackrock Inc. | 0.66% | 403.01K | $527.94K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MAIA
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQeW1fdVE1YzY1NkNTLWQtb2hiUHdZSVR5dXY5ZEp6SlRGNGxnc1d2YVNKMDJRd2lRQ1VNMVlRTTlJZllXQ211NDZsNDZLWDhjMGpBMnFXcldDMVVtS3dtbkNQVTdrOThGRVJFVDVCWTNFX1JqZW1uNW1YTEZSUVZaVFlnUl9uOEhRUHF6az…
Compugen Stock: Better Runway Ahead Of MAIA (NASDAQ:CGEN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQclU0QWxmWHp4U0JWdkZFN3FqZDlNOFljb21QQUhwbTY2a0FpMjRXbmFaeVBJVVYtNTZ5YmpIWHhzaF9ORHlfbWpyejlfN0doZ2QwSjloakZCVm5zSFlTUXg1eUJCZU9UVG84bkZCVmI0UTcwdUFvRjl6YWtTa21YWTBXc0tMWHItR1Bz?o…
MAIA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9pVDl4dE10S3B6STdoSk9GeldJQXp3NGtNa1pqVHgtQnIzT2p3R3pRTGt0amdPZllwMmVtQ21YRzZGMksyUlRCcUl0bU8yR3RxUkY1cUJGbVR3NTFER1hrOTdIM1lZNkhYVngxSXRLVnJJWEY1NHN3?oc=5" target="_blank">MAIA Fo…
MAIA Biotechnology, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPel9NX0Ftc3FfNUZjOXk3V0Q4Ymg3ckd5WkJSNk4yZ3VBUTZWUjExREtITDJZTUthNDF2ckhfREltNnZDRVU5elEzdUxrZG5qR1ZmOU5fM0hJekItX05TQmktR0g5bGtJWkJUSEh1RFY1V0RYcGgzczBqNDBJbDJjTm9McFp1clRFMk8zLW…
MAIA - MAIA Biotechnology Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5jamdCWndVOEVtd2EtMzRmVmlIeUlMcG1tTDE0d08xajV6ZzRhRzIweXp4UnRObEo1SXU3T1p0ejhGTF9EbFE?oc=5" target="_blank">MAIA - MAIA Biotechnology Inc Stock Price and Quote</a> <font…
Maia Biotechnology director Guerrero buys $2,386 in common stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOdXZSWnJ1SGptNk84VUxjb3dKSzk5TG1YQzJGOGNYUzUzZW9rMnBUQkVMQzhuWklVVVdsRzdxalBSYTRSZENSVUsxMlBINWJFTDdKRUpvbFNkc1ViMG9PR3ZIT0FueHpSNklTWVQxN3h6eDFjQWVYblFOR0xGcHlOdGFKWW1OaDVMVEN3d1…
MAIA — Frequently Asked Questions
What is the current share price of MAIA Biotechnology, Inc. (MAIA)?
As of 2026-09-19 21:16 PDT, MAIA Biotechnology, Inc. (MAIA) trades at $1.31 on NYSE American. Its 52-week range is $0.87 to $2.95.
What is the market capitalisation of MAIA?
MAIA Biotechnology, Inc. (MAIA) has a market capitalisation of $79.69M on NYSE American.
What is the P/E ratio of MAIA?
MAIA trades at a trailing price-to-earnings (P/E) ratio of -2.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.85.
Is MAIA a good stock to buy?
This page provides a data-driven analysis of MAIA Biotechnology, Inc. (MAIA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.